Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Liquidia Corporation

< Previous 1 2 Next >
Liquidia Corporation to Present at the 2024 Jefferies Global Healthcare Conference
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) 2024 International Conference on Its Open-Label Safety Study of L606 (Liposomal Treprostinil) in Patients with PAH and PH-ILD
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation to Present at BofA Securities Health Care Conference 2024
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation to Report First Quarter 2024 Financial Results on May 14, 2024
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation Announces Poster Presentation at the Pulmonary Vascular Research Institute 2024 Annual Congress
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powder
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation Announces Updates to Operations Leadership
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation Announces $100 Million in New Financings
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
U.S. Federal Circuit Affirms Earlier PTAB Decision to Invalidate All Claims of United Therapeutics Patent No. 10,716,793 (‘793 Patent)
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Announces Pricing of Public Offering of Common Stock
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation to Report Third Quarter 2023 Financial Results on November 7, 2023
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
FDA Accepts Submission to Add PH-ILD to YUTREPIA™ Label
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
United Therapeutics Corporation Files Lawsuit Alleging Infringement of Tyvaso Patent Already Found to Be Invalid by U.S. Patent Office
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation to Report Second Quarter 2023 Financial Results on August 10, 2023
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Submits Amendment to Add PH-ILD Indication to Tentatively Approved NDA for YUTREPIA™ (treprostinil) Inhalation Powder
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
U.S. Federal Circuit Affirms All District Court Rulings in Patent Litigation
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation and Pharmosa Biopharm Announce Collaboration for Sustained-Release Inhaled Treprostinil Product in North America
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation to Present at the 2023 Jefferies Healthcare Conference
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Announces Poster Presentation at the 2023 American Thoracic Society International Conference
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
Liquidia Corporation Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Liquidia Corporation
Via GlobeNewswire
Tickers LQDA
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.